Japan, U.S. drug companies concealed risk of drug punished by large sums of money

On April 8th, the United States federal court jury awarded $6 billion to Japan’s largest drug company Takeda and Eli Lilly for allegedly concealing the cancer risk associated with its diabetes drug, A ctos (chemical pioglitazone). $3 billion fine. Eli Lilly and Pharmaceutical said on April 9 that it could not agree with the verdict and planned to take all legal measures for the next steps, including appeals.

Takeda Pharmaceutical and Eli Lilly Pharmaceuticals jointly promoted A ctos in the United States from September 1999 to September 2006. In the United States, Adekto entered the US market in 1999 was Takeda Pharmaceutical's oral medication for the treatment of diabetes. Takeda Pharmaceutical Co., Ltd. and pharmaceutical companies such as Pfizer Lilai have adopted joint promotion models in many countries. At the same time, however, the security storm surrounding this drug has not stopped. In 2007, because the violation of regulations may lead to the risk of heart disease, Ektop was forced to require a black box on its packaging to reinforce consumer warnings.

According to the official website of the State Food and Drug Administration, the date for the registration and issuance of Alcox Drugs is August 2, 2012 and is limited to May 26, 2014. In mainland China, more than 20 companies, including Connbay, Shanghai Kaibao, and Tasly, produced the drug.

The reporter called the Takeda Pharmaceutical China headquarters on the 9th and the phone could not be connected.

Eli Lilly and Pharmaceuticals stated on the 9th that in China, Lilly did not participate in the promotion of A ctos. Eli Lilly Pharmaceuticals cannot agree with this decision and plans to take all legal steps to take the next step, including appeals. "We firmly believe that A ctos is an important choice in type 2 diabetes. We will continue to defend our company's rights and face future litigation."

According to the official website of the Food and Drug Administration, in November 2011, the State Food and Drug Administration issued an adverse drug reaction information bulletin and revealed that 573 cases of pioglitazone cases were reported in the database of the National Center for Adverse Drug Reaction Monitoring, and 720 cases of adverse reactions were reported. The main adverse reactions were Edema, headaches, etc., but no cases of bladder cancer were reported.